Curis has received another spark of hope as the FDA lets the biotech resume enrollment for a part of its phase 1/2 study assessing emavusertib in patients with leukemia.

ImmunoGen is rethinking the pivotal program for blood cancer antibody-drug conjugate pivekimab sunirine. After talking to the FDA, the biotech is focusing its phase 2 trial on patients without prior or concomitant hematologic malignancy, causing the top-line data drop to slip from 2022 to 2024.

Amgen has bagged the first randomized clinical trial win in the KRAS inhibitor class of cancer medicines. Beyond just a temporary data disadvantage, the development could bode ill for potential runner-up Mirati Therapeutics.

COVID-19 largely caught the world off guard, leading to a mad scramble to repurpose and develop drugs to curb the impact of SARS-CoV-2. Geoffrey Cumming wants to ensure that next time is different—and is donating 250 million Australian dollars ($171 million) over the next 20 years to make it happen

The public wait for another round of COVID-19 vaccine boosters is finally coming to an end. Wednesday morning, the FDA gave the all-clear to Omicron-targeted COVID-19 shots from Moderna and Pfizer-BioNTech.

LumaBridge, which was formerly Cancer Insight, signed a partnership with the Parker Institute for Cancer Immunotherapy to develop new immunotherapies.

Bayer’s BlueRock Therapeutics has partnered with BioCardia on the delivery of cell therapies, paying a “sizable” upfront fee to access minimally invasive technology that could get its heart failure candidates to their targets.

Fundraising can be a constant headache for many health tech startups—but not for Theranica. The company has managed to keep a steady stream of financing coming in and investors interested in its technology since its 2016 founding.

In a blog post, FDA Commissioner Robert Califf said the agency has launched an Overdose Prevention Framework to combat the opioid crisis. The strategy targets unnecessary prescriptions, prolonged prescribing and counterfeit drugs, while promoting the development of treatments for substance use disorders and education programs for doctors.

Accountable care organizations generated $1.6 billion in savings for Medicare last year, the fifth straight year the program has garnered savings.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.